Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 24, 2024 11:23am
121 Views
Post# 35949478

RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedReportedly the one year survival for Stage IV (advanced or metastatic) cancer patients is 8% which would mean that in ONCY's Phase 2 Goblet-1 pancreatic cancer cohort with 13 evaluable patients, only 1.04 patients should have reached the one year survival milestone.

However in October 2023 ONCY reported that the 12 month survival rate in the evaluated Stage IV patients was 46%,  suggesting that 6 patients were still alive, thus surpassing Stage IV pancreatic cancer historical survival rates by 6 fold.



Summary of Data and Findings from the PDAC Arm of the Phase 1/2 GOBLET Study:

Tumor Responses: Consistent with the abstract, data from the study outlined patient responses, including:

-- Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans)
 
-- A Disease Control Rate (DCR) of 85%
 

Survival data: Evaluated based on 4 parameters including:

-- Median duration of response was 5.7 months

-- Median progression-free survival (PFS) was 7.2 months

-- Interim 12-month survival rate was 46%

-- Interim median overall survival (OS) was 10.6 months

T-Cell Populations: Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed:

-- Mean baseline TIL cell levels of 22%

-- Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones

-- A correlation between the expansion in the blood of TIL-specific clones and tumor response.

https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/




<< Previous
Bullboard Posts
Next >>